Dinshaw Irani Advocates for Mid and Smallcaps as Largecaps Soar to Record Highs on PEG Valuations.
In the latest quarterly earnings report, the Nifty 50 index demonstrated a modest growth of 6% for Q4 FY26 on a year-over-year basis, contrasting sharply with the more robust earnings growth of 28% observed in midcaps and over 41% in smallcaps. This divergence has prompted Helios Mutual Fund to shift its investment strategy, favoring mid and smallcap stocks over largecaps, as exemplified by their recent acquisitions of Adani Enterprises, Dixon Technologies, and CAMS. Such reallocations underscore a strategic pivot to capitalize on the expanding earnings potential in these segments, particularly given that the PEG ratio suggests smallcaps currently offer more favorable valuations compared to largecaps, which may appear cheap based on PE ratios but are expensive when growth is factored in.
Helios has actively managed portfolio exits, trimming positions in Tata Motors and Titan. The decision to reduce exposure to Tata Motors stems from apprehensions regarding the sustainability of commercial vehicle demand amidst rising crude oil prices. Although the exit from Titan may have been premature given the company’s promising growth outlook, the selective approach indicates a prioritization of growth-oriented investments in less mature sectors. On the buying front, the decision to invest in Adani Enterprises aligns with the company’s aggressive expansion into solar energy manufacturing, while Dixon Technologies is seen as a valuable opportunity due to the easing of restrictions surrounding its Chinese joint ventures.
The fund is strategically avoiding sectors such as metals, US-facing pharmaceuticals, and consumer durables. The rationale for steering clear of metals is rooted in concerns over China’s overwhelming global supply dominance. Similarly, US-facing pharma stocks pose risks due to expiring exclusivities and expensive new drug launches. Although there has been minor growth in consumer durables due to increased demand for cooling products amidst a heat wave, the overall market conditions do not warrant significant allocation. Additionally, Helios has trimmed its stake in largecap banks as it reallocates resources toward more promising growth sectors.
In healthcare, Helios’s focus is predominantly on hospital stocks rather than pharmaceuticals, reflecting a belief in the structural scarcity of quality healthcare facilities and the long-term tailwinds from rising per-capita GDP supporting hospital utilization rates. The fund’s operational strategy emphasizes the rapid deployment of incoming cash flows, maintaining minimal idle cash and ensuring continuous investment in high-potential opportunities within the evolving Indian market landscape.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova team.)